Business
Update on Chinook's Investments in Germany
Update on Chinook's Investments in Germany Canada NewsWire BERLIN, Feb. 5, 2019 ...
About this update from Greenrise Global Brands Inc
[{"type":"text","content":"\n\n\n\nUpdate on Chinook's Investments in Germany\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\n\n\nCanada NewsWire\nBERLIN, Feb. 5, 2019\n\n\n\nBERLIN, Feb. 5, 2019 /CNW/ - Chinook Tyee Industry Limited (\"Chinook\") (TSXV: XCX) is an investment finance company with two European subsidiaries, AMP Alternative Medical Products GmbH based in Erfurt, Germany and Mercury Partners & Company plc based in Valletta, Malta. Chinook has 10,217,796 fully diluted shares issued and outstanding and net investment assets of over $2.0 million (unaudited) as of September 30th, 2018.\nAbout AMP Alternative Medical Products (\"AMP\")AMP Alternative Medical Products GmbH, is a biopharmaceutical company based in the German state of Thuringia and provides medical cannabis formulations and dose delivery systems for German patients.\nSince March 2017, German doctors can prescribe medical cannabis to patients suffering from serious illnesses which patients can get filled by pharmacists and generally paid for by German health insurance companies. AMP's business involves the purchase of EU-GMP medical cannabis from third party suppliers, and arranging transportation, logistics and storage services, for ultimate distribution through pharmaceutical distributors to pharmacists in Germany.  \nAccording to analytics firm Prohibition Partners at the 2019 Davos World Economic Forum, Europe's three largest medical cannabis markets, Germany, the Netherlands and Italy, could double in size in 2019, making this a \"transformative\" year for the European market. \nIn Canada, licensed producers of cannabis (\"LPs\") that enter into supply contracts with AMP are audited to ensure they meet EU-GMP standards before AMP arranges for EU-GMP certification.  EU-GMP provides the standards, principles and guidelines of good manufacturing practices for medicinal products used in the European Union and sets the minimum quality standard for cannabis for medical use. For Canadian LPs that do not meet EU-GMP standards, AMP and its German pharmaceu...